IVDの世界市場の動向（2023年3月）

当レポートでは、世界のIVD市場について調査分析し、市場の成長促進要因と動向、COVID-19の影響、製品の動向と新たな発展などをまとめています。

診断検査は、医師が診断に至るための貴重なリソースであり続けています。さらに、医師が病気を診断するための手助けから、精密医療などの治療に関する貴重な情報を医師に提供するものへと変化しています。COVID-19パンデミックの余波を受けた現在、新製品、世界の医療支出の変化、主要市場の規制変更、疾病動向などが、絶えず変化する市場像を生み出す要因の一つとなっていますが、その回復力は衰えることはありません。結局のところ、IVD市場は常に革新的であり、ダイナミックであり続けています。

当レポートにおいて、Kalorama Informationは以下のように分析し、回答しています：

• 2022年第1四半期以降、2023年第1四半期までのIVD市場の成長を牽引しているものは何か？
• 2022年第1四半期以降、2023年第1四半期まで、市場に影響を与えている主要動向は何か？
• COVID-19は市場にどのような影響を与え、今後も与え続けるのか？
• IVD市場を形成する製品動向と新規開拓は？

Kalorama Informationは、IVD市場とその急速に変化する状況について、常に真摯な姿勢で概説しています。Kalorama Informationは、アナリストの豊富な経験と、入手可能な最も正確なデータを提供するという会社のコミットメントにより、これまでも、そしてこれからも、市場にアクセスする上で優れた存在であり続けます。

目次

第1章 世界のIVD市場 - 2023年3月

• IVD市場の需要と成長
• COVID-19診断市場
• 市場セグメントに対するCOVID-19の影響

第2章 製品の動向と新たな発展

• 選択された新しい - 2022年第4四半期と2023年第1四半期 - 主なIVD製品の発売、発展、動向
• イムノアッセイ
• 分子
• 個別化医療
• POC
• シーケンシング
• 選択されたCOVID-19の発展 - 2022年第4四半期 - 2023年第1四半期
• 抗原・抗体
• 分子

第3章 上位のIVD市場参入企業の結果

• 選択された競合リーダーの最新情報
• 2022年のM&A活動
• Abbott Laboratories
• Becton Dickinson and Co
• bioMerieux SA
• Danaher Corporation
• Hologic, Inc.
• QuidelOrtho Corporation
• Roche Diagnostic
• Siemens Healthineers
• Sysmex Corporation
• Thermo Fisher Scientific

第4章 新たな機会

• AIの将来の動向
• 在宅検査
• マルチプレックス検査
• 遠隔医療

Diagnostic testing continues to be a valuable resource to help physicians arrive at a diagnosis. Additionally, it has gone from helping the physician to diagnose illness to providing the physician with invaluable information on treatments such as precision medicine. Now, in the aftermath of the COVID-19 pandemic, new products, changes in global health spending, regulatory changes in major markets and disease trends are among the factors that produce a constantly changing market picture but one that remains resilient. Ultimately, the IVD market remains dynamic, demonstrating constant innovations.

In “IVD Market Trends Report, March 2023 ”, Kalorama Information analyses and answers:

• What's Driving Growth in the IVD Market since Q1 2022 and into Q1 2023?

• What Major Trends have been Affecting the Market since Q1 2022 and into Q1 2023?

• How Has COVID-19 Impacted and Continued to Impact the Market?

• What Product Trends and New Developments Will Shape the IVD Market?

Kalorama Information continues to be diligent in outlining the IVD market and its rapidly changing landscape. Kalorama Information has been and continues to be superior in accessing the market due to the extensive experience of its analysts and commitment by the company to present the most accurate data available.

Table of Contents

Chapter 1: Worldwide IVD Market - March 2023 Update

• IVD Market Demand and Growth
  • Figure 1-1: Quarter-by-Quarter Segment Performance Commentary, 2022
  • Table 1-1: Global In Vitro Diagnostic Sales by Product Market, 2022 ($ million) (Clinical Chemistry; Immunoassays: Infectious disease, Other immunos, Blood bank screening, Drugs of Abuse, Diabetes HbA1c - lab; Hematology - Core Lab; Microbiology (ID/AST); Microbiology (molecular); Microbiology - Mass Spectrometry; Coagulation (PT/INR); Coagulation, molecular; Histology/cytology; HPV, molecular; Nucleic acid assays; Blood grouping/typing; Blood bank molecular - NAT Screens; Circulating tumor cells; POC, OTC diabetes; POC, OTC other; POC, professional/hospital; Mass Spectrometry; Other IVD)
  • Figure 1-2: IVD Segment Performance (Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other), Q1 2022 - Q4 2022 ($MN)
  • Figure 1-3: IVD Segment Performance (Clinical Chemistry, Coagulation, Hematology, Histology, Immunoassay, Microbiology, POC, Other), Total Market Value, 2022 ($MN)
• COVID-19 Diagnostic Markets
  • Table 1-2: COVID-19 Product Sales - Immunoassay (Antigen, Serology), Molecular, Rapid - 2022 ($ millions)
• Effect of COVID-19 on Market Segments
  • Table 1-3: IVD Market excluding and with COVID-19, 2022
  • Figure 1-4: IVD Market Distribution by Segment (COVID-19 Assays and Instruments, IVD Market excluding COVID-19 Assays and Instruments), 2022
  • Figure 1-5: IVD Market by COVID-19 and non-COVID markets, Quarterly Performance, 2022
  • Table 1-4: Global In Vitro Diagnostic Market - YoY Growth 2021-2022
  • Figure 1-6: Global In Vitro Diagnostic Market - YoY Growth, by Segment (Blood Bank Molecular - NAT Screens, Blood Grouping/Typing, Clinical Chemistry, Coagulation (PT/INR), D-Dimer, Diabetes HbA1c lab, Drugs of Abuse, Hematology - Core Lab, Histology/Cytology, Immuno - Blood Bank Screening, Immuno - Infectious Disease, Microbiology (ID/AST), Microbiology (Molecular), Nucleic Acid Assays/genetic Tests, Other Immunos, POC - OTC Diabetes, POC - OTC Other, POC - Professional/Hospital), 2021-2022

Chapter 2: Product Trends and New Developments

• Selected New - Q4 2022 and Q1 2023 - Core IVD Product Launches, Developments and Trends
• Immunoassay
• Molecular
• Personalized Medicine
• POC
• Sequencing
• Selected COVID-19 Developments - Q4 2022 - Q1 2023
  • Figure 2-1: COVID-19 Test Market by Type, Q1-Q4 2022 - COVID-19 Testing Wanes
• Antigen/Antibody
• Molecular

Chapter 3: Top IVD Market Participant Results

• Selected Competitive Leader Updates
  • Figure 3-1: IVD Segment Growth by Leading Competitors (Abbott Diagnostics, Becton Dickinson, bioMerieux, Danaher, Hologic, QuidelOrtho, Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Thermo Fisher Scientific), Change in Sales, 2021-2022
  • Figure 3-2: Changes in Market Distribution for IVD Sales, 2019-2022 - Roche and Abbott Battle for #1 Spot
  • Figure 3-3: Comparison of Total Diagnostic Sales for Abbott vs Roche 2020-2022 (in millions $)
• 2022 M&A Activity
  • Table 3-1: IVD-Relevant M&A Activity, 2022
  • Figure 3-4: Count of IVD Industry M&A Deals by Month, Full Year 2022 and Jan-Feb 2023
• Abbott Laboratories
  • Table 3-2: Abbott Corporate Summary
  • Figure 3-5: Abbott Diagnostics Revenue by Segment (Core Laboratory, Molecular, Point-of-Care, Rapid Diagnostics, COVID-19), Full Year 2021 and 2022 $M
• Becton Dickinson and Co
  • Table 3-3: Becton Dickinson Corporate Summary
  • Figure 3-6: BD Life Sciences, Revenues by Business FY End September 30, 2021, and 2022 $M
• bioMerieux SA
  • Table 3-4: bioMerieux Corporate Summary
  • Figure 3-7: bioMerieux Clinical Applications Segment, Full Year Results, 2021, 2022 € MN
• Danaher Corporation
  • Table 3-5: Danaher Corporation Summary
  • Figure 3-8: Danaher Diagnostic Segment Performance, Full Year Results, 2021 ,2022 $M
• Hologic, Inc.
  • Table 3-6: Hologic Corporate Summary
  • Figure 3-9: Hologic Diagnostic Segment Performance, Full Year Results, FY 2021 and FY 2022, $M
• QuidelOrtho Corporation
  • Table 3-7: QuidelOrtho Corporate Summary
  • Figure 3-10: QuidelOrtho, Full Year Results, by Segment (Immunoassay/Clinical Lab, Molecular Diagnostics, Point-of-Care, Transfusion Medicine) $M (2021, 2022)
• Roche Diagnostic
  • Table 3-8: Roche Diagnostic Corporate Summary
  • Figure 3-11: Roche Diagnostics Revenue by Product Group (Core Lab, Diabetes Care, Molecular, Pathology Lab, Point-of-Care), Full Year Results 2021, 2022, CHF MN
• Siemens Healthineers
  • Table 3-9: Siemens Healthineers Corporate Summary
  • Figure 3-12: Siemens Diagnostics Revenue, FY 2021 and FY 2022, € MN
• Sysmex Corporation
  • Table 3-10: Sysmex Corporate Summary
  • Figure 3-13: Sysmex Revenue by Product Segment (Clinical Chemistry, FCM, Hematology, Hemostasis, Immunochemistry, Urinalysis, Others), FY 2021, 2022 and 2023, JPY MN
• Thermo Fisher Scientific
  • Table 3-11: Thermo Fisher Scientific Corporate Summary
  • Figure 3-14: Thermo Fisher Scientific COVID-19 Response Revenue, 2021 and 2022, by Quarter $B

Chapter 4: New Opportunities

• Artificial Intelligence Future Trends
• At-Home Testing
• Multiplex Testing
• Telehealth